Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.

Liu Z, Zeng B, Sun F, Xia Q

Diabetes care1 Jun 2025Cited by 8 (Europe PMC)

PMID40392993PMCIDPMC12094200DOI10.2337/dc24-2241PepBankPUB-40392993

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewOther
In adults with type 2 diabetes, semaglutide was dominant or cost-effective versus other glucose-lowering medications in 73.9% of all comparisons.
In plain wordsAcross studies in type 2 diabetes, semaglutide was good value compared with other diabetes drugs in most comparisons.
Peptide
Semaglutide
Outcome
Not applicableProportion of comparisons in which semaglutide was dominant or cost-effective
Study
n = 119
Comparator
Other glucose-lowering medications
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
Dominant/cost-effective comparisons
73.9%
all comparisons
Source sentences
Summary
Overall, semaglutide was dominant/cost-effective in 73.9% of all comparisons.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).
Report a problemFND-4039299301
02HumanSystematic reviewOther
Semaglutide was dominant or cost-effective in all comparisons sponsored by Novo Nordisk.
In plain wordsIn studies paid for by Novo Nordisk, semaglutide was judged good value in every comparison.
Peptide
Semaglutide
Outcome
Not applicableCost-effectiveness in Novo Nordisk-sponsored comparisons
Study
n: not reported in source
Comparator
Other glucose-lowering medications
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Source sentences
Summary
semaglutide was found to be dominant/cost-effective in all comparisons sponsored by Novo Nordisk versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).
Report a problemFND-4039299302
03HumanSystematic reviewOther
Semaglutide was dominant or cost-effective in 50.0% of comparisons funded by nonindustry sponsors.
In plain wordsIn studies not funded by industry, semaglutide was judged good value in half of the comparisons.
Peptide
Semaglutide
Outcome
Not applicableCost-effectiveness in nonindustry-funded comparisons
Study
n: not reported in source
Comparator
Other glucose-lowering medications
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Measurements
Dominant/cost-effective comparisons
50%
nonindustry sponsors
Source sentences
Summary
versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).
Report a problemFND-4039299303
04HumanSystematic reviewOther
Semaglutide was dominant or cost-effective in none of the comparisons funded by other industry sponsors.
In plain wordsIn studies paid for by other drug companies, semaglutide was not judged good value in any comparison.
Peptide
Semaglutide
Outcome
Not applicableCost-effectiveness in comparisons funded by other industry sponsors
Study
n: not reported in source
Comparator
Other glucose-lowering medications
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Source sentences
Summary
and in none funded by other industry sponsors.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).
Report a problemFND-4039299304
05HumanSystematic reviewOther
Semaglutide was more cost-effective in high-income countries and in studies with a broader perspective, longer horizon and lower discount rates.
In plain wordsSemaglutide looked better value in high-income countries and in studies with a broader view, longer time span and lower discount rates.
Peptide
Semaglutide
Outcome
Not applicableCost-effectiveness by country income, perspective, horizon and discount rate
Study
n: not reported in source
Comparator
Other glucose-lowering medications
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Additionally, semaglutide was more cost-effective in high-income countries and in studies with adoption of a broader perspective, longer horizon, and lower discount rates.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8).
Report a problemFND-4039299305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.